Rheumatoid Arthritis
Conditions
Brief summary
Proportion of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12
Detailed description
Proportion of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12, Proportion of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12, Proportion of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP), Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE
Interventions
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12, Proportion of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12, Proportion of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP), Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE | — |
Countries
Germany, Poland, Spain
Outcome results
None listed